Science & Research
Tonix Pharmaceuticals Publishes Pharmacokinetic Study Supporting TONMYA's Mechanism for Fibromyalgia Treatment
Tonix Pharmaceuticals' peer-reviewed study demonstrates TONMYA's superior pharmacokinetic profile compared to oral cyclobenzaprine, supporting its use as the first new fibromyalgia treatment in over 15 years.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Kairos Pharma Recognized for Innovation in Overcoming Cancer Drug Resistance
Kairos Pharma Ltd. has been honored with the 2026 Pinnacle Award for its pioneering work on resistance-modulating treatments that aim to enhance the effectiveness of existing cancer therapies.
Analytical Validation Strengthens Soligenix Outlook as Pipeline Advances
A recent Zacks Small-Cap Research report highlights Soligenix's clinical progress and upcoming milestones, particularly in its phase 3 FLASH2 trial for cutaneous T-cell lymphoma treatment, reinforcing the company's strategic credibility and valuation potential.
Jacksonville Family Transforms Type 1 Diabetes Diagnosis Into Advocacy Through Community Initiative
A Jacksonville family's journey with their son's Type 1 diabetes diagnosis has evolved into Pablo's Pack T1D, a community initiative providing resources and support while participating in the Breakthrough T1D Walk to advance research toward a cure.
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine in the second half of 2026, addressing critical global supply constraints for orthopoxvirus vaccines while reporting a reduced net loss of $21.5 million for 2025.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Generation Uranium Identifies High-Priority Drill Targets at Nunavut Project Using Proven Discovery Model
Generation Uranium has defined multiple high-impact drill targets at its Yath Uranium Project in Nunavut by applying exploration methodologies proven successful at the adjacent Angilak Project, positioning the company for its first-ever drilling campaign in one of Canada's most active uranium districts.
Memory Beads Inspired by 116-Year-Old's Habit Launch to Support Alzheimer's Research
A new tactile brain health tool called Peter's Memory Beads, inspired by a 116-year-old man's daily routine, has launched with all proceeds supporting Alzheimer's Association research and services.
NIMS Engineers Develop System to Track Material Design Processes, Enhancing AI Transparency and Reproducibility
Engineers at Japan's National Institute for Materials Science have developed a system called pinax that captures the entire trial-and-error process in material design, addressing critical challenges in reproducibility and accountability for AI-driven scientific discovery.
Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
Two Neuroscientists Awarded 2026 Ralph L. Sacco Scholarships for Brain Health Research
The American Academy of Neurology and the American Heart Association have awarded $150,000 scholarships to Sarah Kettlety and Cali McEntee to study concussion recovery in children and the effects of exercise on brain aging, respectively.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
Soligenix Gains EU Orphan Drug Designation for SGX945 in Behçet's Disease, Bolstering Rare Disease Pipeline
The European Commission granted orphan drug designation to Soligenix's SGX945 for Behçet's disease, validating the therapy's potential and supporting the company's rare disease strategy.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Oncotelic Therapeutics Featured in Editorial Highlighting Biotech's Shift Toward Science-Driven Asset Valuation
A BioMedWire editorial highlights how biotechnology companies like Oncotelic Therapeutics are increasingly seeing scientific progress translate into measurable financial value through fair-value accounting frameworks, with Oncotelic's 45% stake in GMP Bio valued at over $1 billion.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Golden Cariboo Discovers Deep Mineralization at Quesnelle Gold Quartz Mine Property
Golden Cariboo Resources Ltd. has identified potential new mineralization approximately 600 meters below surface at its British Columbia property, advancing the company's understanding of the site's long-term potential as it progresses toward a mineral resource estimate.
New Oral Rinse Demonstrates Superior Gingivitis Protection in Saliva Environment
ioRinse Ultra has shown complete elimination of gingivitis-causing bacteria within 30 seconds in saliva-inclusive testing, addressing a critical gap in traditional oral rinse evaluation that could transform daily oral care routines.
MAX Power Mining Expands Lawson Natural Hydrogen Discovery with 3D Seismic Results
MAX Power Mining Corp. has reported preliminary 3D seismic survey results that significantly expand its Lawson Natural Hydrogen system in Saskatchewan, delineating a large structural closure and identifying high-priority drill targets that enhance the project's commercial potential.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
Soligenix CEO Advocates for Patient-Centric Drug Reformulation to Improve Treatment Access and Adherence
Soligenix CEO Christopher Schaber argues that reformulating therapies to better align with patients' daily lives can enhance treatment access, adherence, and clinical trial success, reflecting a broader industry shift toward patient-centered drug development.